Document:

Server Farm Management Services Agreement

 Exhibit 10(b) 
  
 Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the
Securities and Exchange Commission. 
  

							
	[IBM logo]	  	/	  	[ADVO logo]	  	 

  
 Server Farm
Management Services Agreement 
  
 Amendment No. 3

  
 ADVO, Inc., (“ADVO”), a corporation having a place of
business at One Targeting Centre, Windsor, CT 06095, and International Business Machines Corporation, having its headquarters at Route 100, Somers, New York 10589 (“IBM”), agree that the following terms and conditions amend and/or
supplement the Server Farm Management Services (as amended from time to time, the “Agreement”), dated July 21, 1999, between ADVO and IBM (this “Amendment No.2”). This Amendment No. 3 is effective as of April 1, 2005 and changes
the section(s) of the Agreement as indicated below. Unless modified herein, all other terms defined in the Agreement and any previous amendments will have the same meaning when used in this Amendment No. 3. All terms and conditions of the Agreement
not otherwise specifically amended or supplemented herein remain unchanged and in full force and effect. Without limiting the foregoing, this Amendment No. 3 expressly supercedes and terminates (without penalty) the following Statements of Work:
[***]. 
  
 Notwithstanding anything to the contrary contained in any such
Statement of Work, no termination charge shall be due in connection with such termination and no further charges shall be payable under such Statements of Work, as any residual charges have been accounted for in the revised Annual Service Charge
under the Agreement. 
  
 In the event of any inconsistency between the
terms of the Agreement and the terms of this Amendment No. 3, the terms of this Amendment will apply. ADVO and IBM may be referred to individually as a “Party” and collectively as the “Parties.” 
  
 In the event the Agreement for Information Technology Services between ADVO and IBM dated
July 16, 1996 expires or is terminated by the Parties, its terms and conditions will still remain in effect for the purposes of this Agreement and this Amendment No. 3 
  
 1.0 Background and Purpose 
  
 This Amendment No. 3 expressly modifies and amends the Agreement by (1) extending the Agreement Term, (2) updating the pricing, including all executed SOWs under the
Agreement, and (3) updating Schedules as noted below in Section 2.0 Changes. The Parties agree that all Schedules that are a part of the Agreement, except Schedules that are modified by this Amendment, shall be reviewed and updated, as mutually
agreed, on or before May 31, 2005, and reflected in a subsequent contract amendment to the Agreement. 
  
 2.0 Changes 
  

	a)	Section 2.3 (Term), is hereby deleted in its entirety and replaced with the following: “The Term of this Agreement will begin as of 12:01 a.m. on the Effective Date and
will end as of 12:00 midnight on December 31, 2012, unless earlier terminated or amended per the terms and conditions the Agreement 

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission.

  

					
	IBM/ADVO Confidential	 	-1-	 	 

	b)	Subsection 3.c of Schedule E-1 (Service Level Objectives and Service Level Agreements) to the Agreement is hereby amended by the addition of the following sentence at the end of the
subsection: 

  
 [***]

  

	c)	Schedule B (Supported Server System Software), is hereby deleted in its entirety and replaced with the revised Schedule B, attached hereto. 

  

	d)	Schedule C (Supported Server Application Software) is hereby deleted in its entirety and replaced with the revised Schedule C, attached hereto. 

  

	e)	Schedule D (Supported Servers), including Schedule D-1 ADVO Machines, Schedule D-2 IBM Machines, and Schedule D-3 Standard Configurations, are hereby deleted in their entirety and
replaced with the revised Schedule D, including Schedule D-1, D-2, and D-3 attached here. 

  

	f)	Schedule F (Rollout Plan Timeline), is hereby deleted in its entirety. 

  

	g)	Schedule H (Tools) is hereby deleted in its entirety and replaced with the revised Schedule H, attached hereto. 

  

	h)	Schedule J, Section 11.0 (Machine and Hardware Purchase) is hereby deleted in its entirety. 

  

	i)	Schedule J-1 (Annual Service Charges), J-2 (Supported Server/LPARs Baselines), and J-3 (Termination Charges) are all hereby deleted in their entirety and replaced with revised
Schedule J-1, J-2, and J-3, attached hereto. 

  

	j)	The “Monthly ARC” table set forth in Schedule J, Section 6.0 (Additional Resource Charges (“ARC”)) is hereby deleted in its entirety and the table set forth in
Schedule J-2 attached hereto is substituted therefor. 

  

	k)	The “Monthly RRC” table set forth in Schedule J, Section 7.0 (Reduced Resource Charges (“RRC”)) table is herby deleted in its entirety and the table set forth in
Schedule J-2 attached hereto is substituted therefor. 

  
 3.0
Assumptions 
  

	a)	[***] 

  

	b)	[***] 

  

	c)	All IBM owned servers will be refreshed as stated in Schedule D-Supported Servers. Equipment will be refreshed with additional relative performance at an assumed 10% year-over-year
increase to be implemented at the time of refresh. 

  

	d)	[***] 

  

	e)	[***] 

  

	f)	[***] 

  

	g)	[***] 

  

	h)	[***] 

  

	i)	[***] 

  

	j)	[***] 

  

	k)	[***] 

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission.

  

					
	ADVO/IBM Confidential	 	-2-	 	 

	l)	[***] 

  

	m)	IBM reserves the right to substitute equivalent configurations for the servers and storage based on availability at time of procurement with ADVO’s prior written consent, which
consent shall not be unreasonably withheld or delayed. 

  

	n)	Prior to IBM ordering any hardware or software associated with any scheduled refresh, the Parties agree to discuss ADVO’s then-current requirements and work together to
evaluate alternative hardware and software architectures and strategies for acquisition of hardware and software, which strategies, after December 31, 2006, may include ADVO acquiring hardware and software from third parties to be supported by IBM.
Upon request, IBM will prepare, at IBM’s expense and in good faith, a proposal that reflects ADVO’s requested alternative architectures and acquisition strategy. Upon acceptance by ADVO of any IBM proposal, IBM will amend the Annual
Service Charge in the Agreement to reflect the new proposal. IBM agrees that there is no “minimum commitment” by ADVO under the Agreement, and IBM will assure that any new proposal will reflect charges only for those Services requested by
ADVO and no amount will be included to compensate IBM for any reduction in the aggregate Annual Service Charge under the Agreement. Notwithstanding the foregoing, ADVO will continue to be obligated to pay the Annual Service Charge specified in
Schedule J-1, as amended from time to time, until the Parties agree upon the implementation of an alternative configuration for hardware and software and amend Schedule J-1, as contemplated above. IBM agrees that it will not order any hardware or
software associated with any scheduled refresh without providing ADVO with prior notice and receiving ADVO’s written approval, which approval will not be unreasonably withheld or delayed. 

  

	o)	Section 4.17 (Benchmarks) of the Agreement is hereby deleted in its entirety and the following substituted therefor: 

  
 Benchmarking Reviews 
  
 (a) From time to time during the Term after the second anniversary of the
Effective Date of this Amendment (but no more often than once in any 12 month period), ADVO may, subject to this Section, engage the services of an independent third party (a “Benchmarker”) to compare the quality and cost of the Services
for some or all of the Services provided under the Agreement against the quality provided and price charged by other service providers to other entities receiving comparable services in order to ensure that ADVO is obtaining pricing and levels of
service that are competitive with market rate prices and service levels, given the nature, volume and type of Services being benchmarked (all of which will be described by the Parties in the benchmark agreement) (“Benchmarking”). The
Benchmark will be designed to provide a representative comparison of the benchmarked Services provided by vendors across various industries. ADVO and IBM shall each pay 50% of the fees and expenses charged by the Benchmarker (which fees will not be
contingency-based). 
  
 ADVO and IBM expressly agree as of the
Effective Date of this Amendment the following constitutes a list of acceptable organizations to perform a Benchmark: 
  
 1) [***] 
  
 2) [***] 
  
 3) Any other independent third-party agreed upon by the Parties from time to time during the term. 
  
 (b) Any acceptable Benchmarker engaged by ADVO shall execute a
non-disclosure agreement reasonably satisfactory to IBM and ADVO. IBM shall cooperate fully with ADVO and the Benchmarker, provide all reasonable data relating to the provision of 
  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission.

  

					
	ADVO/IBM Confidential	 	-3-	 	 

 the Services requested by the Benchmarker (but in no event shall IBM be required to provide IBM cost
data or data relating to other IBM customers), provide reasonable access to the Benchmarker during such effort, all at IBM’s cost and expense. The Benchmarking shall be conducted so as not to unreasonably interfere with IBM’s ability to
perform the Services in accordance with the Performance Standards. 
  
 (c) ADVO will determine the scope of the study and the Services to be compared (the “Benchmarked Services”). The Benchmarker shall perform a price-based benchmark analysis, comparing the aggregate charges applicable to the
Benchmarked Services, against the aggregate charges incurred for similar services by the selected entities in the Representative Sample (as such term is defined below). The comparison must determine and account for differences in the scope or
circumstances of service delivery that impede a reasonable “like for like” comparison. Consequently, the Benchmarker shall “normalize” the data used to perform the comparison in order to account for differences between the volume
of services, scope of services, service levels, complexity, degree of standardization, terms and conditions, asset purchases by IBM solely associated with the performance of this Agreement that have been approved, in writing, by ADVO, service
delivery and receipt location(s) to the extent relevant, and other relevant factors and those applicable to the entities comprising the Representative Sample. Such normalization must ensure that the results of the Benchmark provide as accurate a
comparison as reasonably possible by making appropriate adjustments to all data relating to each of the selected entities in the Representative Sample to account for any and all differences between the Benchmarked Services performed by IBM and the
services received by the respective entity, including any additional and/or value added services required to be performed by IBM under the Agreement and not received by such entity. IBM may elect to disclose to the Benchmarker additional measuring
or estimating data, which the Benchmarker may consider and account for in its normalization calculations. For the purposes of this Section: 
  
 (i) “Representative Sample” for Benchmarked Services shall mean a sample of a minimum of four (4) entities proposed by the Benchmarker that
shall only include customers with similar scope, service levels and volume and similar complexity as the Benchmarked Services. 
  
 (ii) “Benchmarked Level” shall mean the average costs attributable to the Benchmarked Services among those entities comprising the
Representative Sample. 
  
 (d) Prior to performing the
comparison, the Benchmarker shall meet with the Parties to review and explain its Benchmark methodology, including how each of entities in the Representative Sample matches and does not match the relevant factors of this Agreement and how the
normalization approach will be applied. The Benchmarker shall provide a written summary of the Benchmark methodology and shall perform the Benchmark substantially as described in its written summary. 
  
 (e) If the Benchmark Results indicate that the Benchmarked Level is [***]

  
 (f) If the Benchmarker finds that [***]  

 
 (g) Review and Dispute. ADVO shall provide IBM with a copy of the
Benchmarker’s report and IBM shall have 60 days to review such report, and contest the Benchmarker’s findings. As part of such review, either Party may request the Benchmarker to provide sufficient information to allow the Party to
validate the Benchmark, but neither Party shall be permitted to request the identity of the third party service provider or any customer included in the Representative Sample. If the Parties are unable to agree upon the validity of the
Benchmarker’s findings, the matter shall be resolved pursuant to the dispute resolution procedures set forth in Section 16.2. Any reductions or increases in IBM’s Charges shall be implemented on a prospective basis within 60 days after the
date the Benchmarker’s final report was 
  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission.

  

					
	ADVO/IBM Confidential	 	-4-	 	 

 
first provided to IBM. Notwithstanding anything to the contrary herein, in the event that IBM disputes the validity of the Benchmarker’s findings or
ADVO’s election to terminate the Agreement pursuant to this provision, and IBM submits the dispute for resolutions pursuant to the dispute resolution procedures set forth in Section 16.2, IBM agrees that it will pay 100% of all of the
Benchmarkers charges for performing the Benchmark and supporting the Benchmark findings and all reasonable legal fees incurred by ADVO in the event that IBM elects to initiate proceedings for judicial resolution of the dispute. 
  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission.

  

					
	ADVO/IBM Confidential	 	-5-	 	 

 THE PARTIES ACKNOWLEDGE THAT THEY HAVE READ THIS AMENDMENT NO. 3, UNDERSTAND IT, AND AGREE TO BE BOUND BY ITS TERMS
AND CONDITIONS. FURTHER, THE PARTIES AGREE THAT THE COMPLETE AND EXCLUSIVE STATEMENT OF THE AGREEMENT BETWEEN THE PARTIES RELATING TO THIS SUBJECT SHALL CONSIST OF 1) THIS AMENDMENT NO. 3; 2) THE ATTACHMENTS TO THIS AMENDMENT NO. 3; 3) THE SERVER
FARM MANAGEMENT SERVICES AGREEMENT, DATED JULY 21, 1999, AS AMENDED 3) ITS SCHEDULES AND 4) ITS EXHIBITS. THIS STATEMENT OF THIS AMENDMENT NO. 3 SUPERSEDES ALL PROPOSALS OR OTHER PRIOR AGREEMENTS, ORAL OR WRITTEN, AND ALL OTHER COMMUNICATIONS
BETWEEN THE PARTIES RELATING TO THE SUBJECT MATTER DESCRIBED IN THIS AMENDMENT NO. 3. 
  

							
	Accepted by:	 	Accepted by:
	ADVO, Inc.	 	International Business Machines Corporation
				
	By:	 	 /s/ S. SCOTT HARDING

	 	By:	 	 /s/ NORMAN KOREY

	 	 	Authorized Signature	 	 	 	Authorized Signature
				
	 	 	 S. Scott Harding

	 	 	 	 Norman Korey

	 	 	Name (Type or Print)	 	 	 	Name (Type or Print)
		
	Date: As of March 31, 2005	 	Date: April 1, 2005

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission.

  

					
	ADVO/IBM Confidential	 	-6-	 	 

 Schedule J-1 
  
 Annual Service Charges 
  
 Server Farm 
  

																	
	 	  	 2005 (Starting
 April 1)

	  	2006

	  	2007

	  	2008

	  	2009

	  	2010

	  	2011

	  	2012

	 New ASC
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Alternate Blade
Configuration Charge – ARC if requested by ADVO 
  
 Blade Server
Option 
  

																	
	 	  	 2005 (Starting
 April 1)

	  	2006

	  	2007

	  	2008

	  	2009

	  	2010

	  	2011

	  	2012

	 ASC
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission.

  

					
	ADVO/IBM Confidential	 	-7-	 	 

 Schedule J-2 
  
 Supported Server/LPARs Baselines 
  

																	
	 BASELINE

	  	2005

	  	2006

	  	2007

	  	2008

	  	2009

	  	2010

	  	2011

	  	2012

	 Supported Server/LPARS
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

	*	[***] 

  
 Additional Resource Charges (“ARC”) 
  

							
	 	  	 Monthly ARC

	  	 	  	 
	 LPAR Baseline, Plus One
	  	[***]	  	 	  	 
	 LPAR Baseline, Plus Two
	  	[***]	  	 	  	 
	 LPAR Baseline, Plus Three
	  	[***]	  	 	  	 
	 LPAR Baseline, Plus Four
	  	[***]	  	 	  	 
	 LPAR Baseline, Plus Five
	  	[***]	  	 	  	 
	 LPAR Baseline, Plus Six
	  	[***]	  	 	  	 
	 LPAR Baseline, Plus Seven
	  	[***]	  	 	  	 
	 	  	[***]	  	[***]	  	every
	 	  	[***]	  	[***]	  	[***]
	 LPAR Baseline, Plus Eight
	  	[***]	  	 	  	 

  
 Reduced Resource
Charges (“RRC”) 
  

			
	 	  	 Monthly RRC

	 LPAR Baseline, Minus One
	  	[***]
	 LPAR Baseline, Minus Two
	  	[***]
	 LPAR Baseline, Minus Three
	  	[***]
	 LPAR Baseline, Minus Four
	  	[***]
	 LPAR Baseline, Minus Five
	  	[***]
	 LPAR Baseline, Minus Six
	  	[***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission.

  

					
	ADVO/IBM Confidential	 	-8-	 	 

 Schedule J-3 
  
 Termination Charges 
  
 Termination 
  

																	
	 	  	 2005 (Starting
 4/1)

	  	2006

	  	2007

	  	2008

	  	2009

	  	2010

	  	2011

	  	2012

	 Termination Charge
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

	*	ADVO agrees not to terminate this Agreement for its convenience earlier than January 1, 2007 subject to the other provisions of this Agreement, unless mutually agreed to by IBM.

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission.

  

					
	ADVO/IBM Confidential	 	-9-	 	 

 Schedule B 
  
 Supported Server System Software 
  

											
	Vendor

	 	Product

	 	Installed
Version

	 	Oper.
Resp.

	 	Fin.
Resp.

	 	Maint.
Resp.

	Base (All Systems)	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  
 For purposes of this Schedule B,
Operational Responsibility means: 
  
 Installation and
customization of Supported Server System Software 
 Problem determination and resolution 
 System or product level security 
 Performance
monitoring and tuning 
  
 For purposes of this Schedule B, Financial
Responsibility means: 
  
 Supported Server System Software
license owner 
  
 For purposes of this Schedule B, Maintenance Responsibility
means: 
  
 Planned version, release, modification, and
service pack upgrades (including installation and tuning) 
  
 Application of Supported Server System Software patches when applicable Interaction with Supported Server System Software vendor for additional product support 
  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	 	- 1 -	 	 

 Schedule C 
 Supported Server Application Software 
  

											
	Vendor

	 	Product

	 	Installed
Version

	 	Oper.
Resp.

	 	Fin.
Resp.

	 	Maint.
Resp.

	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	 	1 of 5	 	Amendment No. 3

											
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
						
	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

	[***]	Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	 	2 of 5	 	Amendment No. 3

																
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
						
	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
						
	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
						
	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
						
	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
						
	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
						
	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]

  

	[***]	Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Securities and Exchange Commission 

  

					
	IBM/ADVO Confidential	 	3 of 5	 	Amendment No. 3

																
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]
	[***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]	 	[	***]

	[***]	Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Securities and Exchange Commission 

  

					
	IBM/ADVO Confidential	 	4 of 5	 	Amendment No. 3

 For purposes of this Schedule C, Operational Responsibility means: 
  

	 	•	 	Installation and customization of Supported Server Application Software 

  

	 	•	 	Problem determination and resolution 

  

	 	•	 	System or product level security 

  

	 	•	 	Performance monitoring and tuning 

  

	 	•	 	Running anti-virus software 

  
 For purposes of this Schedule C, Financial Responsibility means: 
  

	 	•	 	Supported Server Application Software license owner 

  
 For purposes of this Schedule C, Maintenance Responsibility means: 
  

	 	•	 	Planned version, release, modification, and service pack upgrades (including installation and tuning) 

  

	 	•	 	Application of Supported Server Application Software patches when applicable 

  

	 	•	 	Interaction with Supported Server Application Software vendor for additional product support 

  

	 	•	 	Support operational requests from database administrators 

  
 Note: 
  
 [***] 

	[***]	Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Securities and Exchange Commission 

  

					
	IBM/ADVO Confidential	 	5 of 5	 	Amendment No. 3

 Schedule D 
  
 Supported Servers 
  
 The following Schedules D-1 (ADVO Machines) and D-2 (IBM Machines) identify the Supported Servers for which IBM will provide the Services. Schedule D-3
describes the configuration of each Supported Server identified in Schedule D-1 or D-2. 
  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 1 of 54

 Schedule D-1 (ADVO Machines) 
  

																			
	Model

	 	Serial No.

	 	Installation
Date

	 	Retirement
Date

	 	 Application
 as of
installation
date

	 	Vendor

	 	CNFG

	 	Location as of
Effective Date

	 	Date to be
installed in
IBM Data
Center/IBM
Location

	 	Description

	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	 	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	 
	[***]	 	            [***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
										
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	    [***]	 	            [***]	 	 	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
										
	    [***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
										
	    [***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
										
	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	    [***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	    [***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
										
	[***]/	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 2 of 54

 Schedule D-2 (IBM Machines) 
  

																					
	Model

	 	Serial
Number

	 	 Installation
 Date

	 	 Retirement
 Date*

	 	 Refresh 1
 Date

	 	 Refresh 2
 Date

	 	Cfg #

	 	Vendor

	 	Server
Name

	 	 Current
 Location

	 	Description

	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
											
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
											
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
											
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 3 of 54

																					
	Model

	 	Serial
Number

	 	 Installation
 Date

	 	 Retirement
 Date*

	 	 Refresh 1
 Date

	 	 Refresh 2
 Date

	 	Cfg #

	 	Vendor

	 	Server
Name

	 	 Current
 Location

	 	Description

	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
											
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 4 of 54

	*	[***] 

  

	**	[***] 

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 5 of 54

 Schedule D-3 
  
 Configuration 1 ADVO [***] 
  
 [***] 
  
 HARDWARE 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 6 of 54

					
	  [***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
			
	SOFTWARE	 	 	 	 
			
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

  
 End of Configuration 1

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 7 of 54

 Configuration 2 ADVO [***] 
  
 [***] 
 HARDWARE 
  

					
	Product

	 	Description

	 	 
	  [***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 8 of 54

					
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	  [***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
			
	SOFTWARE	 	 	 	 
			
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
			
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
			
	                      [***].	 	 	 	 
			
	[***]	 	[***]	 	[***]
			
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

  
 End of Configuration 2

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 9 of 54

 Configuration 3 ADVO [***] 
  
   [***] 
 HARDWARE

  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 10 of 54

 SOFTWARE 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

  
 End of Configuration 3

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 11 of 54

 Configuration 4 [***] 
  
 HARDWARE 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 12 of 54

					
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
			
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 13 of 54

					
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

  
 ******************************** SOFTWARE *** 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
			
	 	 	        [***]	 	 
			
	[***]	 	[***]	 	[***]
	                    [***]	 	 	 	 
	[***]	 	[***]	 	[***]
	                    [***]	 	 	 	 
	                    [***]	 	 	 	 
			
	 	 	        [***]	 	 
	[***]	 	[***]	 	[***]
	        [***]	 	                        [***]	 	                        [***]

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 14 of 54

							
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]            	 	[***]                        	 	[***]                        	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	 	 	 	 	[***]
	 	 	[***]                	 	 	 	 

  
 End of Configuration 4

  
 Configuration 5 [***] 
 HARDWARE 
  

							
	Product

	 	Description

	 	Qty

	 	 
	[***]	 	[***]                        	 	[***]                        	 	 
	                [***]	 	[***]	 	[***]	 	 
	                [***]	 	[***]	 	[***]	 	 
	                [***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	            [***]	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	            [***]	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 15 of 54

 SOFTWARE 
  

					
	Product

	 	Description

	 	Qty

	[***]            	 	[***]                            	 	[***]                            
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
			
	[***]            	 	[***]                            	 	[***]                            
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

  
 End of Configuration 5

  
 Configuration 6 [***] 
  
 [***] 
 HARDWARE 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]                            	 	[***]                            
	                    [***]	 	[***]	 	[***]
	                    [***]	 	[***]	 	[***]
	                    [***]	 	[***]	 	[***]
	                    [***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	            [***]	 	 	 	 

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 16 of 54

					
	[***]	 	[***]	 	[***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
			
	[***]            	 	[***]                            	 	[***]                            
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
			
	[***]            	 	[***]                            	 	[***]                            
	            [***]	 	 	 	 
	[***]	 	[***]	 	[***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	[***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 17 of 54

 SOFTWARE 
  

					
	Product

	 	Description

	 	Qty

	[***]            	 	[***]                            	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
			
	 	 	[***]	 	 
			
	[***]            	 	[***]                            	 	[***]                            
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

  
 End of Configuration 6

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 18 of 54

 Configuration 7 [***] 
  
 [***] 
 HARDWARE 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	            [***]	 	                        [***]	 	                        [***]
	            [***]	 	                        [***]	 	                        [***]
	            [***]	 	                        [***]	 	                        [***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 19 of 54

					
	[***]            	 	[***]                            	 	[***]                            
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
			
	[***]            	 	[***]                            	 	[***]                            
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
			
	[***]            	 	[***]                            	 	[***]                            

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 20 of 54

					
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	[***]	 	[***]	 	[***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
			
	[***]	 	[***]	 	[***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
			
	[***]	 	[***]	 	[***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 21 of 54

					
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

  
 *********************************
SOFTWARE ***** 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	        [***]	 	        [***]	 	        [***]
	        [***]	 	        [***]	 	        [***]
	        [***]	 	        [***]	 	        [***]
	        [***]	 	        [***]	 	        [***]
	        [***]	 	        [***]	 	        [***]
	        [***]	 	        [***]	 	        [***]
	        [***]	 	        [***]	 	        [***]
	        [***]	 	        [***]	 	        [***]
	        [***]	 	        [***]	 	        [***]
	        [***]	 	        [***]	 	        [***]
	        [***]	 	        [***]	 	        [***]
			
	 	 	  [***]	 	 
			
	[***]	 	[***]	 	[***]
	        [***]	 	        [***]	 	        [***]
	        [***]	 	        [***]	 	        [***]
			
	[***]	 	[***]	 	[***]
	        [***]	 	        [***]	 	        [***]

  
 End of Configuration 7

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 22 of 54

 Configuration 8 
  
 [***] 
 HARDWARE 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	            [***]
	[***]	 	[***]	 	            [***]
	[***]	 	[***]	 	            [***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	            [***]
	[***]	 	[***]	 	            [***]
	[***]	 	[***]	 	            [***]
	[***]	 	[***]	 	            [***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	            [***]
	[***]	 	[***]	 	            [***]
	[***]	 	[***]	 	            [***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	            [***]
	[***]	 	[***]	 	            [***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	            [***]
	[***]	 	[***]	 	            [***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	            [***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	            [***]
	[***]	 	[***]	 	            [***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	            [***]
	            [***]	 	 	 	 
	[***]	 	[***]	 	            [***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 23 of 54

					
	            [***]	 	 	 	 
	    [***]	 	            [***]	 	            [***]
	            [***]	 	 	 	 
	[***]                	 	[***]	 	[***]
	            [***]	 	 	 	 
	        [***]	 	            [***]	 	            [***]
	            [***]	 	 	 	 
	        [***]	 	            [***]	 	            [***]
	            [***]	 	 	 	 
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	            [***]	 	 	 	 
	        [***]	 	            [***]	 	            [***]
	            [***]	 	 	 	 
	        [***]	 	            [***]	 	            [***]
	            [***]	 	 	 	 
	        [***]	 	            [***]	 	            [***]
	            [***]	 	 	 	 
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
			
	 	 	    [***]	 	 
	 	 	[***]	 	 
	[***]              	 	    [***]	 	[***]
	            [***]	 	 	 	 
	        [***]	 	            [***]	 	            [***]
	            [***]	 	 	 	 
	        [***]	 	            [***]	 	            [***]
	            [***]	 	 	 	 
	        [***]	 	            [***]	 	            [***]
	            [***]	 	 	 	 
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	            [***]	 	 	 	 
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 24 of 54

					
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	      [***]	 	[***]             [***]	 	                        [***]
	      [***]	 	 	 	 
	[***]	 	            [***]	 	            [***]
	      [***]	 	 	 	 
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	      [***]	 	 	 	 
	[***]	 	            [***]	 	            [***]
	      [***]	 	 	 	 
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
			
	 	 	[***]	 	 
			
	[***]	 	[***]	 	[***]
	            [***]	 	 	 	 
			
	            [***]	 	 	 	 
	[***]	 	            [***]	 	            [***]
	            [***]	 	 	 	 
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	            [***]	 	 	 	 
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	[***]	 	            [***]	 	            [***]
	            [***]	 	 	 	 
	[***]	 	            [***]	 	            [***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 25 of 54

					
	        [***]	 	 	 	 
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	        [***]	 	 	 	 
	    [***]	 	            [***]	 	            [***]
	        [***]	 	 	 	 
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
			
	 	 	  [***]	 	 
			
	[***]	 	[***]	 	[***]
	        [***]	 	 	 	 
	    [***]	 	            [***]	 	            [***]
	        [***]	 	 	 	 
	    [***]	 	            [***]	 	            [***]
	        [***]	 	 	 	 
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	        [***]	 	 	 	 
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	[***]	 	[***]	 	[***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	        [***]	 	 	 	 
	    [***]	 	            [***]	 	            [***]
	        [***]	 	 	 	 
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	        [***]	 	 	 	 
	    [***]	 	            [***]	 	            [***]
	        [***]	 	 	 	 
	    [***]	 	            [***]	 	            [***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 26 of 54

					
	     [***]
	 	        [***]	 	        [***]
	     [***]
	 	        [***]	 	        [***]
	     [***]
	 	        [***]	 	        [***]
	     [***]
	 	        [***]	 	        [***]
	 	 	         [***]
	 	         [***]

			
	 	 	[***]	 	 
			
	 [***]
	 	[***]	 	[***]
	     [***]
	 	         [***]
	 	         [***]

	         [***]
	 	 	 	 
	     [***]
	 	        [***]	 	        [***]
	         [***]
	 	 	 	 
	 [***]
	 	[***]	 	[***]
	         [***]
	 	 	 	 
	     [***]
	 	        [***]	 	        [***]
	         [***]
	 	 	 	 
	     [***]
	 	        [***]	 	        [***]
	     [***]
	 	        [***]	 	        [***]
	     [***]
	 	 	 	 
	         [***]
	 	        [***]	 	        [***]
	     [***]
	 	 	 	 
	         [***]
	 	        [***]	 	        [***]
	     [***]
	 	        [***]	 	        [***]
	     [***]
	 	 	 	 
	         [***]
	 	 	 	 
	         [***]
	 	        [***]	 	        [***]
	     [***]
	 	 	 	 
	     [***]
	 	 	 	 
	         [***]
	 	        [***]	 	        [***]
	     [***]
	 	 	 	 
	     [***]
	 	        [***]	 	        [***]
	     [***]
	 	        [***]	 	        [***]
	     [***]
	 	        [***]	 	        [***]
			
	 	 	 [***]
	 	 

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 27 of 54

 SOFTWARE 
  

							
	 Product

	 	 Description

	 	 Qty

	 	 
	 [***]
	 	 	 	 	 	        [***]
	     [***]
	 	        [***]	 	        [***]	 	 
	     [***]
	 	        [***]	 	        [***]	 	 
	 	 	    [***]	 	 	 	 
	 [***]
	 	[***]	 	[***]	 	 
	         [***]
	 	 	 	 	 	 
	 [***]
	 	[***]	 	[***]	 	 
	         [***]
	 	 	 	 	 	 
	 [***]
	 	[***]	 	        [***]	 	 
	     [***]
	 	        [***]	 	        [***]	 	 
	     [***]
	 	        [***]	 	        [***]	 	 
	     [***]
	 	        [***]	 	        [***]	 	 
	     [***]
	 	        [***]	 	        [***]	 	 
	     [***]
	 	        [***]	 	        [***]	 	 
	     [***]
	 	        [***]	 	        [***]	 	        [***]
	     [***]
	 	 	 	 	 	 
	     [***]
	 	        [***]	 	        [***]	 	 
	     [***]
	 	        [***]	 	        [***]	 	 
	     [***]
	 	        [***]	 	        [***]	 	 
	     [***]
	 	        [***]	 	        [***]	 	 

  
 End of Configuration
8 

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 28 of 54

 Configuration 9 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	    [***]	 	            [***]	 	            [***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
			
	[***]	 	[***]	 	[***]
			
	    [***]	 	            [***]	 	            [***]
	[***]	 	[***]	 	[***]
			
	[***]	 	[***]	 	[***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	[***]	 	[***]	 	[***]
	    [***]	 	            [***]	 	            [***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 29 of 54

					
	    [***]	 	    [***]	 	    [***]
	    [***]	 	    [***]	 	    [***]
			
	[***]	 	[***]	 	[***]
	            [***]	 	            [***]	 	            [***]

  
 End of Configuration 9

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 30 of 54

 Configuration 10 
  

									
	[***]	 	[***]	 	 	 	[***]	 	[***]
	 	 	[***]	 	[***]	 	 	 	[***]
	 	 	[***]	 	[***]	 	 	 	[***]
	 	 	[***]	 	[***]	 	 	 	[***]
	 	 	[***]	 	[***]	 	 	 	[***]
	 	 	[***]	 	[***]	 	 	 	[***]
	 	 	[***]	 	[***]	 	 	 	[***]
	 	 	[***]	 	[***]	 	 	 	[***]
	 	 	[***]	 	[***]	 	 	 	[***]
	 	 	[***]	 	[***]	 	 	 	[***]
	 	 	[***]	 	[***]	 	 	 	[***]
	 	 	[***]	 	[***]	 	 	 	[***]
	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	 	 	  [***]	 	[***]	 	 	 	[***]
	 	 	[***]	 	[***]	 	 	 	[***]
	 	 	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	[***]	 	 	 	[***]
	 	 	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	 	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	[***]	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	[***]	 	 

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 31 of 54

									
	[***]	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	[***][***]	 	 
	[***]	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	 	 	[***]	 	 
	  [***]	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	 	 	[***]	 	 

  
 End of Configuration 10

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 32 of 54

 Configuration 11 
  

							
	[***]	 	[***]	 	[***]	 	 
				
	IBM SKU

	 	Description

	 	Qty

	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 

  
 End of Configuration 11

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 33 of 54

 Configuration 12 ADVO [***] 
  
 [***] 
  
 HARDWARE 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	    [***]	 	            [***]	 	            [***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 34 of 54

					
	[***]	 	[***]	 	[***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
			
	[***]	 	[***]	 	[***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
			
	[***]	 	[***]	 	[***]
	    [***]	 	            [***]	 	            [***]

  
 End of Configuration 12

  
 Configuration 13 ADVO [***] 
  
 [***] 
 Hardware [***] 
  
 HARDWARE 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	 	 	[***]	 	 
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]
	    [***]	 	            [***]	 	            [***]

  
  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 35 of 54

					
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
			
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]
			
	[***]	 	[***]	 	[***]
	            [***]	 	 	 	 
	        [***]	 	            [***]	 	            [***]
			
	        [***]	 	            [***]	 	            [***]
	        [***]	 	            [***]	 	            [***]

  
 End of Configuration
13 
  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 36 of 54

 Configuration 14 [***] 
  

Hardware [***] 
  
 ********************************* HARDWARE 
  

					
	Product

	 	Description

	 	Qty

	  [***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	            [***]	 	            [***]	 	            [***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 37 of 54

					
	             [***]
	 	             [***]
	 	             [***]

	 [***]
	 	 [***]
	 	 [***]

	 	 	 [***]                [***]
	 	                 [***]

	 [***]
	 	 [***]
	 	 [***]

	             [***]
	 	             [***]
	 	             [***]

	 [***]
	 	 [***]
	 	 [***]

	 [***]
	 	 [***]
	 	 [***]

	 [***]
	 	 [***]
	 	 [***]

	 [***]
	 	 [***]
	 	 [***]

	 [***]
	 	 [***]
	 	 [***]

	 [***]
	 	 [***]
	 	 [***]

	 [***]
	 	 [***]
	 	 [***]

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 38 of 54

 ********************************* SOFTWARE 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
			
	[***]	 	[***]	 	[***]
	            [***]	 	            [***]	 	            [***]
			
	[***]	 	[***]	 	[***]
	            [***]	 	            [***]	 	            [***]
			
	  [***]	 	[***]	 	[***]
	            [***]	 	            [***]	 	            [***]
			
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	            [***]	 	            [***]	 	            [***]
	 	 	[***]                [***]	 	                        [***]
			
	[***]	 	[***]	 	[***]
			
	            [***]	 	            [***]	 	            [***]
	 	 	[***]                [***]	 	                        [***]
	            [***]	 	            [***]	 	            [***]
			
	[***]	 	[***]	 	[***]
	            [***]	 	            [***]	 	            [***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 39 of 54

 ********************************* HARDWARE [***] 
 ********************************* 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
			
	[***]	 	[***]	 	[***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]

  
 *********************************
SOFTWARE 
 ********************************* 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 40 of 54

 ********************************* HARDWARE 
 ********************************* 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	 	 	[***]	 	 
	 	 	[***]	 	 
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
			
	[***]	 	[***]	 	[***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]

  
 *********************************
SOFTWARE 
 ********************************* 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 41 of 54

 ********************************* HARDWARE 
 ********************************* 
  

							
	Product

	 	Description

	 	 	 	Qty

	[***]	 	[***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]

  
 End of Configuration 14

  
 Configuration 14- [***] 
 Hardware [***] 
  
 *************************** HARDWARE[***] 
 ***************************

  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 42 of 54

							
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	 
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	    [***]	 	[***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]

  
 ************************** HARDWARE
[***] 
 ************************** 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 43 of 54

							
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	            [***]
				
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
				
	    [***]	 	    [***]	 	 	 	    [***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 44 of 54

							
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]

  
 *************************** HARDWARE
[***] 
 [***]*************************** 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	    [***]	 	 	 	 	 	 
	[***]	 	 	 	 	 	 
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]
	[***]	 	[***]	 	 	 	[***]

  
 *************************** SOFTWARE
[***] 
 *************************** 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 45 of 54

							
	                        [***]	 	                        [***]	 	 	 	[***]
	                        [***]	 	                        [***]	 	 	 	[***]
	                        [***]	 	                        [***]	 	 	 	[***]
	                        [***]	 	                        [***]	 	 	 	[***]
	                        [***]	 	                        [***]	 	 	 	[***]
	                        [***]	 	                        [***]	 	 	 	[***]
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	    [***]	 	[***]	 	[***]	 	 
	                    [***]	 	                        [***]	 	 	 	[***]
	[***]	 	[***]	 	[***]	 	 
	                    [***]	 	                        [***]	 	 	 	[***]
	        [***]	 	                        [***]	 	 	 	[***]
	        [***]	 	                        [***]	 	 	 	[***]
	                        [***]	 	                        [***]	 	 	 	[***]
	[***]	 	[***]	 	[***]	 	 
	        [***]	 	[***]	 	[***]	 	 
	        [***]	 	                        [***]	 	 	 	[***]
	                        [***]	 	                        [***]	 	 	 	[***]
	                        [***]	 	[***]	 	[***]	 	 
	        [***]	 	                        [***]	 	 	 	[***]
	                        [***]	 	                        [***]	 	 	 	[***]

  
 ************************** SOFTWARE
[***] 
 ************************** 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	                        [***]	 	                        [***]	 	 	 	[***]
	                        [***]	 	                        [***]	 	 	 	[***]
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	                            [***]	 	                        [***]	 	 	 	[***]
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 46 of 54

							
	[***]	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	            [***]
	      [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	      [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	      [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]
	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	            [***]

  
 ************************* SOFTWARE
[***] 
 ************************* 
  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 47 of 54

							
	Product	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]

  
 ************************* SOFTWARE
[***] 
 ************************* 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]

  
 ************************* SOFTWARE
[***] 
 ************************* 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]

  
 ************************* SOFTWARE
[***] 
 ************************* 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]

  
 ************************* SOFTWARE
[***] 
 ************************* 
  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 48 of 54

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]

  
 ************************* SOFTWARE
[***] 
 ************************* 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]

  
 *************************** HARDWARE
[***] 
 *************************** 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	 	 	[***]	 	[***]	 	 
	[***]	 	[***]	 	[***]	 	[***]
	            [***]	 	[***]	 	[***]	 	 
	            [***]	 	[***]	 	[***]	 	 
	            [***]	 	[***]	 	[***]	 	 
	            [***]	 	[***]	 	[***]	 	 

  
 ************************** HARDWARE
[***] 
 ************************** 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 49 of 54

							
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]

  
 *************************** SOFTWARE
[***] 
 *************************** 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]

  
 ************************** SOFTWARE
[***] 
 ************************** 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	        [***]	 	        [***]	 	 	 	[***]
	        [***]	 	        [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	            [***]

  
 *************************** HARDWARE
[***] 
 *************************** 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 50 of 54

							
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]

  
 ************************** HARDWARE
[***] 
 ************************** 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	            [***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]

  
 *************************** SOFTWARE
[***] 
 *************************** 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]

  
 ************************** SOFTWARE
[***] 
 ************************** 
  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 51 of 54

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]

  
 *************************** HARDWARE
[***] 
 *************************** 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]

  
 ************************** HARDWARE
[***] 
 ************************** 
  

							
	Product

	 	Description

	 	Serial

	 	Qty

	[***]	 	[***]	 	[***]	 	 
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]
	            [***]	 	            [***]	 	 	 	[***]

  
 End of Configuration 14 - [***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 52 of 54

 Configuration 15 [***]–[***] 
  
 Hardware [***] 
  
 HARDWARE 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	  [***]	 	 	 	 
	[***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***].
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]
	      [***]	 	            [***]	 	            [***]

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 53 of 54

 SOFTWARE 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	[***]	 	[***]	 	[***]

  
 HARDWARE 
  

					
	Product

	 	Description

	 	Qty

	[***]	 	[***]	 	[***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]
	            [***]	 	            [***]	 	            [***]

  
 End of Configuration 15

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	IBM/ADVO Confidential	  	Schedule D
Amendment 3	  	Page 54 of 54

 Schedule F 
  
 Schedule F has been deleted in its entirety 
  
 Information redacted pursuant to a Confidential treatment request. An Unredacted version has been filed separately With the Securities and Exchange Commission 

 

					
	Technical Solution Outline	 	Page 1 of 1	 	 IBM/Advo Confidential
 March 31, 2005

 Schedule H – Tools 
  
 1.0 ADVO Tools 
  

													
	Quantity
of
Licenses

	 	Description of Tool

	 	Vendor

	 	Oper.
Resp.

	 	 Fin.
 Resp.

	 	Maint.
Resp.

	 	 Dev.
 Resp.

	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	 	 	 	 	 	 	 	 	 
	 	 	[***]	 	 	 	 	 	 	 	 	 	 
	 	 	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	 	 	 	 	 	 	 	 	 
	 	 	[***]	 	 	 	 	 	 	 	 	 	 
	 	 	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 	 	[***]	 	 	 	 	 	 	 	 	 	 
	 	 	[***]	 	 	 	 	 	 	 	 	 	 
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	 IBM/ADVO Confidential
	 	-1-	 	 

 2.0 IBM Tools 
  

													
	Quantity
    of
Licenses

	 	Description of Tool

	 	Vendor

	 	Oper.
Resp.

	 	 Fin.
 Resp.

	 	Maint.
Resp.

	 	 Dev.
 Resp.

	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  
 For purposes of this Schedule H,
Operational Responsibility means: 
  

	 	•	 	Installation and customization of Tools 

  

	 	•	 	Problem determination and resolution 

  

	 	•	 	System or product level security 

  

	 	•	 	Performance monitoring and tuning 

  
 For purposes of this Schedule H, Financial Responsibility means: 
  

	 	•	 	Tool license owner 

  
 For purposes of this Schedule H, Maintenance Responsibility means: 
  

	 	•	 	Planned version, release, modification, and service pack upgrades (including installation and tuning) 

  

	 	•	 	Application of patches to Tool when applicable 

  

	 	•	 	Interaction with Tool vendor for additional product support 

  

	 	•	 	Support operational requests from database/tool administrator 

  
 Note: [***] 

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission

  

					
	 IBM/ADVO Confidential
	 	-2-Agreement for NetWorkStation Management Services

 Exhibit 10(c) 
  
 [IBM logo]    /    [ADVO logo] 
  
 ADVO, Inc. 
  
 Agreement for NetWorkStation Management Services 
  
 Amendment No. 5 
  
 ADVO Inc., (“ADVO”), a corporation having a place of business at One Targeting Centre, Windsor, CT 06095, and International Business Machines Corporation,
having its headquarters at Route 100, Somers, New York 10589 (“IBM”) agree that the following terms and conditions (this “Amendment”) amend and/or supplement the Agreement for NetWorkStation Management Services (“the NWS
Agreement”), dated April 1, 1998, between ADVO and IBM. This Amendment changes the section(s) of the NWS Agreement as indicated below. Unless modified herein, all other terms defined in the NWS Agreement and any previous Amendments shall have
the same meaning when used in this Amendment. All terms and conditions of the NWS Agreement and its prior Amendments not otherwise specifically amended or supplemented herein shall remain unchanged and in full force and effect. 
  
 ADVO and IBM may be referred to individually as a “Party” and collectively as
the “Parties”. 
  
 This Amendment is effective as of April 1,
2005. 
  

	1.0	Background and Purpose: 

  
 The Parties have mutually agreed to extend the Term of the NWS Agreement to December 31, 2012. The Parties agree that all Schedules that are a part of this NWS Agreement
shall be reviewed and updated as mutually agreed, on or before May 31, 2005 and reflected in a subsequent contract amendment to this NWS Agreement. 
  

	2.0	Changes and Additions 

  

	 	a.	In Section 2.3 (Term) of the NWS Agreement, the end date of December 31, 2008 is herby deleted and replaced with December 31, 2012 

  

	 	b.	Subparagraph (a) of Section 4.0 of Schedule F of the NWS Agreement is hereby amended by the addition of the following sentence: 

  
 [***] 
  

	 	c.	The Parties agree to create a joint planning committee that will meet, at least monthly, to review the ADVO measurement package in order to identify and monitor the results of
implementation of technological advancements and process improvements that will reduce the number of Service Requests arising from common causes, enhance the end-user experience and otherwise improve the value achieved 

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission.

  

					
	IBM/ADVO Confidential	 	March 31, 2005, No5	 	Page 1 of 7

 by ADVO from the Services. Unless otherwise required under the Agreement, neither ADVO or IBM are
required to implement any technological advancements or process improvements identified by the joint planning committee. Examples of improvement could be: automation recommendations, enhanced end user training, application changes and the like.

  

	 	d.	The first paragraph of Section 4.4 (Technological Advancements) of the NWS Agreement is hereby by deleted and the following is substituted therefor: 

  
 “IBM agrees to take reasonable action,
taking into account economic circumstances, without an increase in charges to ADVO, subject to the provisions of Section 6.5 and the Service Level Agreement, to provide the Services to ADVO at a technological level that will enable ADVO to take
advantage of technological advancement in its industry and, potentially, improve the quality and efficiency of the Services.” 
  

	 	e.	Subparagraph c) of Section 4.5 (Management and Control) of the NWS Agreement is hereby deleted in its entirety and the following substituted therefore:

  
 “Upon reasonable request by ADVO, IBM
will provide periodic reports to ADVO that will include, at a minimum, the following: 
  
 1) a monthly performance report documenting IBM’s performance with respect to the Service Level Agreements; and, 
  
 2) a monthly report describing ADVO’s utilization of each particular type of RU during such month, and comparing such utilization to the then
applicable Baseline for each RU. 
  
 IBM will provide ADVO with
such documentation and other information as may be reasonably requested by ADVO from time to time in order to verify the accuracy of the reports specified above. Without limiting the foregoing, at ADVO’s request, on a semi-annual basis, IBM
shall provide ADVO with sufficiently detailed data, in electronic form, such as e-mail as mutually agreed, to facilitate ADVO’s audit and validation of monthly performance reports prepared by IBM.” 
  

	 	f.	Section 4.17 (Benchmarks) of the NWS Agreement is hereby deleted in its entirety and the following substituted therefor: 

  
 Benchmarking Reviews 
  
 (a) From time to time during the Term after the second anniversary of the
Effective Date of this Amendment (but no more often than once in any 12-month period), ADVO may, subject to this Section, engage the services of an independent third party (a “Benchmarker”) to compare the quality and cost of the Services
for some or all of the Services provided under the Agreement against the quality provided and price charged by other service providers to other entities receiving comparable services in order to ensure that ADVO is obtaining pricing and levels of
service that are competitive with market rate prices and service levels, given the nature, volume and type of Services being benchmarked (all of which will be described by the Parties in the benchmark agreement) (“Benchmarking”). The
Benchmark will be designed to provide a representative comparison of the benchmarked Services provided by vendors across various industries. ADVO and IBM shall each pay 50% of the fees and expenses charged by the Benchmarker (which fees will not be
contingency-based). 
  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission.

  

					
	IBM/ADVO Confidential	 	March 31, 2005, No5	 	Page 2 of 7

 ADVO and IBM expressly agree as of the Effective Date of this Amendment the following constitutes a list
of acceptable organizations to perform a Benchmark: 
  
 1) [***] 
  
 2) [***] 
  
 3) Any other independent third-party agreed upon by the
Parties from time to time during the term. 
  
 (b) Any acceptable
Benchmarker engaged by ADVO shall execute a non-disclosure agreement reasonably satisfactory to IBM and ADVO. IBM shall cooperate fully with ADVO and the Benchmarker, provide all reasonable data relating to the provision of the Services requested by
the Benchmarker (but in no event shall IBM be required to provide IBM cost data or data relating to other IBM customers), provide reasonable access to the Benchmarker during such effort, all at IBM’s cost and expense. The Benchmarking shall be
conducted so as not to unreasonably interfere with IBM’s ability to perform the Services in accordance with the Performance Standards. 
  
 (c) ADVO will determine the scope of the study and the Services to be compared (the “Benchmarked Services”). The Benchmarker shall perform a
price-based benchmark analysis, comparing the aggregate charges applicable to the Benchmarked Services, against the aggregate charges incurred for similar services by the selected entities in the Representative Sample (as such term is defined
below). The comparison must determine and account for differences in the scope or circumstances of service delivery that impede a reasonable “like for like” comparison. Consequently, the Benchmarker shall “normalize” the data
used to perform the comparison in order to account for differences between the volume of services, scope of services, service levels, complexity, degree of standardization, terms and conditions, asset purchases by IBM solely associated with the
performance of this Agreement that have been approved, in writing, by ADVO, service delivery and receipt location(s) to the extent relevant, and other relevant factors and those applicable to the entities comprising the Representative Sample. Such
normalization must ensure that the results of the Benchmark provide as accurate a comparison as reasonably possible by making appropriate adjustments to all data relating to each of the selected entities in the Representative Sample to account for
any and all differences between the Benchmarked Services performed by IBM and the services received by the respective entity, including any additional and/or value added services required to be performed by IBM under the Agreement and not received
by such entity. IBM may elect to disclose to the Benchmarker additional measuring or estimating data, which the Benchmarker may consider and account for in its normalization calculations. For the purposes of this Section: 
  
 (i) “Representative Sample” for Benchmarked Services shall mean a
sample of a minimum of four (4) entities proposed by the Benchmarker that shall only include customers with similar scope, service levels and volume and similar complexity as the Benchmarked Services. 
  
 (ii) “Benchmarked Level” shall mean the average costs attributable
to the the Benchmarked Services among those entities comprising the Representative Sample. 
  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission.

  

					
	IBM/ADVO Confidential	 	March 31, 2005, No5	 	Page 3 of 7

 (d) Prior to performing the comparison, the Benchmarker shall meet with the Parties to review and explain
its Benchmark methodology, including how each of entities in the Representative Sample matches and does not match the relevant factors of this Agreement and how the normalization approach will be applied. The Benchmarker shall provide a written
summary of the Benchmark methodology and shall perform the Benchmark substantially as described in its written summary. 
  
 (e) If the Benchmark Results indicate that the Benchmarked Level is [***] 
  
 (f) If the Benchmarker finds that-[***] 
  
 (g) Review and Dispute. ADVO shall provide IBM with a copy of the Benchmarker’s report and IBM shall have 60 days to
review such report, and contest the Benchmarker’s findings. As part of such review, either Party may request the Benchmarker to provide sufficient information to allow the Party to validate the Benchmark, but neither Party shall be permitted to
request the identity of the third party service provider or any customer included in the Representative Sample. If the Parties are unable to agree upon the validity of the Benchmarker’s findings, the matter shall be resolved pursuant to the
dispute resolution procedures set forth in Section 16.2. Any reductions or increases in IBM’s Charges shall be implemented on a prospective basis within 60 days after the date the Benchmarker’s final report was first provided to IBM.
Notwithstanding anything to the contrary herein, in the event that IBM disputes the validity of the Benchmarker’s findings or ADVO’s election to terminate the Agreement pursuant to this provision, and IBM submits the dispute for
resolutions pursuant to the dispute resolution procedures set forth in Section 16.2, IBM agrees that it will pay all of the Benchmarkers charges for supporting the Benchmark findings in connection with any dispute that is escalated pursuant to
Section 16.2 and all reasonable legal fees incurred by ADVO in the event that IBM elects to initiate proceedings for judicial resolution of the dispute.  
  

	 	g.	Exhibit J-1 to Schedule J (Charges, Measures of Utilization and Financial Responsibilities) to the NWS Agreement is hereby deleted in its entirety and replaced by the revised
Exhibit J-1 attached hereto.  

  

	 	h.	In order to preserve ADVO’s flexibility to achieve the costs savings inherent in the transfer of the Services to one of IBM’s off-shore or near-shore facilities,
IBM has agreed to submit to ADVO a proposal for implementing such a transfer and reducing the overall ASC hereunder for the remainder of the Term effective not later than January 1, 2007, or earlier upon ADVO’s reasonable request. Such proposal
will include a 90-day pilot project to direct a select group of Service Requests to one of IBM’s off-shore or near-shore facilities, the cost of which shall be shared equally by the Parties.  

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission.

  

					
	IBM/ADVO Confidential	 	March 31, 2005, No5	 	Page 4 of 7

 THE PARTIES ACKNOWLEDGE THAT THEY HAVE READ THIS AMENDMENT, UNDERSTAND IT, AND AGREE TO BE BOUND BY ITS TERMS AND
CONDITIONS. FURTHER, THE PARTIES AGREE THAT THE COMPLETE AND EXCLUSIVE STATEMENT OF THE AGREEMENT BETWEEN THE PARTIES RELATING TO THIS SUBJECT SHALL CONSIST OF 1) THIS AMENDMENT, INCLUDING THE ATTACHMENTS TO THIS AMENDMENT; AND 2) THE NWS AGREEMENT
DATED APRIL 1, 1998, AS AMENDED. THIS STATEMENT OF THE AMENDMENT SUPERSEDES ALL PROPOSALS OR OTHER PRIOR AGREEMENTS, ORAL OR WRITTEN, AND ALL OTHER COMMUNICATIONS BETWEEN THE PARTIES RELATING TO THE SUBJECT MATTER DESCRIBED IN THIS AMENDMENT.

  

							
	Accepted by:	 	Accepted by:
		
	ADVO, Inc.	 	International Business Machines Corporation
				
	By:	 	 /s/ S. Scott Harding

	 	By:	 	 /s/ NORMAN KOREY

	 	 	Authorized Signature	 	 	 	Authorized Signature
		
	 S. Scott Harding

	 	 Norman Korey

	Name (Type or Print)	 	Name (Type or Print)
		
	Date: As of March 31, 2005	 	Date: April 1, 2005

  

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission.

  

					
	IBM/ADVO Confidential	 	March 31, 2005, No5	 	Page 5 of 7

 Exhibit J-1 
  
 Annual Service Charges 
  

																	
	 	  	2005 (Starting
April 1)

	  	2006

	  	2007

	  	2008

	  	2009

	  	2010

	  	2011

	  	2012

	 Gross ASC
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 Annual Credit
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 Net ASC
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Baseline 

	*	For informational purposes only, the Parties expect a monthly average of [***] IMAC events per business day, including primary site installs. Because this Agreement provides for
dedicated on-site resource(s), no ARCs/RRCs for the primary site for hardware and software IMACs, software break/fixes or Build/PDPs will be applied and such events will not count against the Baseline.  

  
 Monthly Baselines and ARC/RCC Rates 
  

											
	 CATEGORY

	  	 UNIT

	  	ARC RATE ($)

	  	RRC RATE ($)

	  	 BASELINE
 (per month)

	  	RRC
Point

	Non-primary site Installs & MACs (including software break/fix) and Build PDPs (ARC/RRC calc. per weighted event, as described below)	  	per Event	  	[***]	  	[***]	  	[***]	  	[***]
						
	Service Requests	  	per Service Request	  	[***]	  	[***]	  	[***]	  	[***]

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission.

  

					
	IBM/ADVO Confidential	 	March 31, 2005, No5	 	Page 6 of 7

 Weighted Event - Install and MAC Services 
  

			
	 Event Service Description

	  	Weight per Event

	 Build/PDP
	  	[***]
	 Install
	  	[***]
	 Move
	  	[***]
	 S/W Add
	  	[***]
	 S/W Change
	  	[***]
	 H/W Add
	  	[***]
	 H/W Change
	  	[***]

  
 ARCs for Installs and MAC Services
will be calculated as follows: per event X ARC Rate X Weighted Factor = the ARC Rate. For example, for an ARC of two Remote Installs the calculation will be: [***]. The ARC for the two Remote Installs will be [***]. 
  
 Other Charges and Fees/Per Event/Unit Prices 
  

					
	 	  	 UNIT

	  	US RATE ($)

	 Dispatch Service
	  	per Hour	  	[***]

  
 Termination Charge 

 
 New Contract ADVO view 
  

																	
	 	  	 2005
 (Starting
April 1)

	  	2006

	  	2007

	  	2008

	  	2009

	  	2010

	  	2011

	  	2012

	 Termination
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

	**	ADVO agrees not to terminate this NWS Agreement for its convenience earlier than January 1, 2007 subject to the other provisions of this NWS Agreement, unless mutually agreed to by
IBM. 

	[***]	Information redacted pursuant to a confidential treatment request. An unredacted version has been filed separately with the Securities and Exchange Commission.

  

					
	IBM/ADVO Confidential	 	March 31, 2005, No5	 	Page 7 of 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}]]